MPX International (CSE: MPXI) (OTC: MPXOF) - Investor Dashboard

MPX International Corp
CSE Symbol: MPXI
Market Focus: Global
Classification: Vertically Integrated
Country: Canada
Employees: 225
Established: 2018
CEO: Scott Boyes


Fiscal Year-End: September
Facilities: 3
Dried Flower: Production
Extracts: Production
Auditor: MNP
Headquarters: Toronto, Ontario

Financials (06/30/19)

Cash on hand: C$23.4 million
Fixed Investment: C$3.9 million
Shareholders’ Equity: C$70.7 million
Revenues – Last Quarter: C$0.7 million
Adj. Gross Margin : 60.3%
EPS : -C$0.01

Capital Structure (08/29/19)

Last Financing: 56.1 million Units at C$0.48
Basic Shares: 131.4 million
Warrants: 59.9 million
Options: 3.5 million
Diluted Shares: 196.9 million


Company Brief

MPX International (CSE: MPXI) (OTC: MPXOF) is a vertically integrated cannabis company based in Canada that was formerly part of MPX Bioceutical when it sold select U.S. assets to iAnthus Capital Holdings for $800 million in stock. This newly-formed company, MPX International, then acquired all of the non-U.S assets from MPX Bioceutical and is now aggressively building shareholder value by now focusing on the production, distribution and retailing of high quality cannabis distillates and derivative products for the Canadian and global medical and adult use cannabis markets. The company has a global footprint with presence in six markets.

After the spinout, MPX International assets include Spartan Wellness, Canveda, Salus BioPharma, HolyWeed, and beleaf. The company’s focus is to manufacture and market consumer product goods which include cannabiniods as their primary active ingredient.

MPX Brands

FY19-Q2 Corporate Structure


  • Licensed and GMP-certified Canadian cultivation and processing facility: Canveda
  • Construction in process on a 20,000-square-foot cultivation facility in Owen Sound, Ontario
  • Wholly-owned Spartan Wellness operates as a medical cannabis clinic in Canada
  • 15 licensed dispensaries in five states
  • Operates Swiss CBD company, HolyWeed
  • Joint venture to develop cannabinoid products with Israeli-based pharmaceutical company Panaxia
  • GMP-ready pharmaceutical facility in Malta
  • Operating in six countries

Growth Strategy

  • Retail development in Western Canada with seven to 10 outlets projected for 2019
  • Three industrial-grade extraction labs in development
  • 5.2 million grams of high-CBD distillate from flower harvest completed 10/2019
  • Convert Spartan Wellness patients to Canveda after sales license
  • European expansion of HolyWeed
  • Leveraging U.S. and Canadian expertise across international markets including the U.K., Switzerland, Malta, South Africa, and Australia
  • Plans to launch CBD and terpene infused beverages, edibles, and vaporizers


  • Scalable international facilities and low cost production provide MPXI Labs a competitive advantage
  • Organic certification in Switzerland for its HolyWeed CBD products
  • Pharmaceutical-grade CBD products through Salus Biopharma
  • U.K. CBD retail through beleaf
  • Canada’s largest veteran distribution network: Spartan Wellness
  • Medical Cannabis Learning Network: kiosks in clinics and pharmacies designe to drive patient engagement
  • MPX Australia: Access to Asian and Oceania markets through licensed indoor cultivation and in-development industrial-grade extraction lab

MPX Distribution Model

Curated Stories & News

Visit MPX International,

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. MPX International Corporation is a client of NCV Media, LLC. Read our full disclaimer.